Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results in motor neuron death and has no approved treatment yet. Around 20% of ALS cases are caused by Cu, Zn human superoxide dismutase (SOD1) aggregation into amyloid fibrils. First step of potential strategies to combat the disease could be finding an effective aggregation inhibitor in vitro. However, only a few studies for SOD1 protein have been done in this field for now. They involve in vitro screening of 640 FDA approved drugs [1], several flavonoids[2] and curcumin[3] only. Our goal was to test inhibitory effect of a small molecule methylene blue, which has been shown to inhibit Alzheimer's disease-linked amyloid beta oligomerization[4].
Recombinant SOD1 was purified from E. Coli by Ni2+ affinity chromatography. Aggregation experiments were carried out in 10 mM potassium phosphate, 0.5 M GuHCl and 5 mM DTT buffer solution, pH 7.4. Kinetics of aggregation was monitored using Thioflavin T (ThT) fluorescence assay. Morphology of aggregates was visualised by atomic force microscopy and secondary structure was tested by infrared spectroscopy.
The presence of methylene blue leads to reduced ThT fluorescence intensity and results in different morphology as well as secondary structure of aggregated protein. Seeded aggregation kinetics suggests that methylene blue possibly modulates surface properties of pre-added fibrils without affecting stability of protein monomer, but further investigation is needed to reveal the exact methylene blue mode of action.